Get started
PFIZER INCPFIZER INCPFIZER INC

PFIZER INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

$PFE - From hard on pills to covid. A story of corruptionIt is not really a story of corruption. It is crazy that the two most successful times in this company's career was by creating Viagra and creating Covid...errrr I mean the vaccine for one of the covid strands....sometimes...when it works. Screw it though!!! The government is giving them billions and billions of dollars for no reason!!! Let the good time roll baby!! I think she will retest the breakout and then continue higher for as long as a democrat is president. I mean covid exists. Dang it....you know what I mean. As long as the US government funnels them billions unnecessarily. I cant stand the CEO and he should be in jail. I choose to be in MRK or many others instead. Not that they are really much better, but PFE CEO is truly an evil person. Good luck to you crazy people who stick with it. This is not a recommendation to buy or sell. It is for informational purposes only.
NYSE:PFE
by UnknownUnicorn16739272
2
Pfizer: Ready to Shoot Lower? Pfizer - Short Term - We look to Sell at 49.33 (stop at 51.54) The trend of lower highs is located at 53.50. Previous support located at 50.00. A move through bespoke support at 50.00 and we look for extended losses. Closed below the 20-day EMA. The medium term bias remains bearish. Our profit targets will be 43.51 and 41.00 Resistance: 54.00 / 57.00 / 60.00 Support: 50.00 / 45.00 / 40.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:PFEShort
by Saxo
2
$PFE - Sitting on the neck line... In my previous chart I was leaning on head and shoulder not playing out. But now with war about to break out in Ukraine, I am not so sure that the neckline area of $50.25 will hold. We have been on an uptrend that started since March 2021 and has checked back to the trend line once before. If we were to check back to the trend line again after the head and shoulder neckline breaks, it could close the gap at $45.99. I will be watching $50.25 - $49 area to see if that support can hold. If it breaks, the bear case will play out and we can see $45.99. Bear Target 1 - $45.99 Neckline - $50.25 Bull case - bounce from neck line and move towards $62. ——————————————————— How to read my charts? - Matching color trend lines shows the pattern. Sometimes a chart can have multiple patterns. Each pattern will have matching color trend lines. - The yellow horizontal lines show support and resistance areas. - Fib lines also show support and resistance areas. - The dotted white lines show the price projection for breakout or breakdown target. Disclaimer: Not investment advice.
NYSE:PFELong
by PaperBozz
1
Pfizer - PFE - is this the end of Pfizer?I guess Pfizer's stock price could help us with knowing when this Covid nightmare might be drawing to a close. This count suggests that we might be about to begin a 5th of a 5th of a 5th. If this count has any merit and the trend does end then we can expect some serious downside to this stock some time in the not too distant future. (A more bearish count could be made for a completed 5th wave already taking place and I show that with the blue count, but the red count is my preferred count.)
NYSE:PFELong
by tomj2417
Pfizer Analysis 08.02.2022Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next few days and weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. I will personally reply to every single comment! If you enjoyed this analysis, I would definitely appreciate it, if you smash that like button and maybe consider following my channel. Thank you for watching and I will see you tomorrow!
NYSE:PFE
by basictradingtv
10
Pfizer - Might get worse! 😨-The reason why PFE is dropping is not the economical situation but rather the COVID situation which is getting lighter (at least in folk's mind) every day. -We got omicron but it being a light virus almost like a flu also didn't catch much attention lately. -This stock throughout the pandemic depended on negative news, whoever is chaos oriented invested in this company, but lets all agree that the better the health situation gets and less of a tragedy COVID becomes, the less attention will be on this stock. -Not to say that the company is worthless now but it wont have the hype it had for sure! -Earnings are forecasted to decline on average of 6.2% per year. OUR TARGET PRICE: $45-$50
NYSE:PFE
by caldooninvestment
2
Pfizer, and why you keep old notesI got an alert on Pfizer NYSE:PFE just now that on the 30m a Tradingview Spike Alert I had setup fired. This is following research I did over the weekend to the Support level that PFE reached in the recent down move. While doing that I found an old annotation from November 2020 earnings that informed a long term dividend investment play. It's nice to see how something has performed over the long term to remind an investor to buy and hold good companies. The company has earnings tomorrow.
NYSE:PFE
by norok
1
$PFE - Downtrend Reversal - 4 Day Inside Bar - Upcoming CatalystNYSE:PFE A hammer signaled reversal for $PFE. Shortly after price broke out of the downtrend resistance. Four inside bars have formed during period of consolidation. $PFE looks primed for sharp movement. Catalyst would likely be FDA / CDC approval/rejection of its Covid vaccination for children, expected in 4th week of Feb. Application is for 2 doses, though 3 would be required. Application and study for 3rd shot are expected to be submitted during the initial application review phase. This is one ticker to be aware of. Biased long, but willing to play both sides.
NYSE:PFELong
by TheGritz
$PFE - Possible broadening wedge breakout Looking like the stock might be in the process of breaking out of that Broadening wedge. Although there is a possibility of head and shoulder completion, I am not sure it will play out. However, there is earning coming up on Feb 8 that could decide which pattern will play out. Here is how I see it. If the price breaks above $55, the bullish case will play out and price could reach $64. But if the price breaks below $50 and more importantly $49, the bearish case will play out with potential fall to $45. But I am leaning bullish case. Bullish target 1 - $56 Bullish target 2 - $64 Risk - the price breaks down to $45 and fill the gap. ——————————————————— How to read my charts? - Matching color trend lines shows the pattern. Sometimes a chart can have multiple patterns. Each pattern will have matching color trend lines. - The yellow horizontal lines shows support and resistance areas. - Fib lines also shows support and resistance areas. - The dotted white lines shows price projection for breakout or breakdown target. Disclaimer: Do your own DD. Not an investment advice.
NYSE:PFELong
by PaperBozz
1
Pfizer | Fundamental Analysis | MUST READ | LONG 🔔Historically, Pfizer has not had much momentum when it comes to stock performance. Over the past ten years, the S&P 500 Index has outperformed this large pharmaceutical company. But now Pfizer is gaining momentum. Last year it outperformed the benchmark index - Pfizer was up 60%, while the S&P 500 was up 27%. And today's Pfizer doesn't look much like Pfizer did a few years ago. In 2020, the company completed the separation of its Upjohn business, eliminating an element that was driving down revenues. Today, Pfizer has many "best sellers," a new coronavirus drug, and a full development cycle. So is it worth investing in this drug maker in 2022? First, let's look at the company's Covid business. Pfizer is a leading supplier of vaccines in many parts of the world. In the U.S., the company has fully vaccinated more than 118 million people. But overseas, Pfizer's vaccine business is actually even bigger. The company claims that it generates 75% of its revenues from vaccine sales outside the United States. The European Union recently exercised an option to supply more Pfizer vaccines, bringing the total number of doses of Pfizer vaccines to be delivered this year to over 650 million. The full agreement, signed last spring, calls for up to 1.8 billion doses to be delivered to the region by 2023. In Pfizer's latest earnings report, the company projected vaccine revenue of $36 billion for all of 2021. But this year could turn out to be even more successful for Pfizer than last year. Here's why. Vaccine orders remain high -- but with the addition of a new coronavirus product. Late last year, Pfizer received approval for the emergency use of Paxlovid, an oral coronavirus treatment. Paxlovid is a pill that should be given at the first sign of infection. The drug's main ingredient blocks the action of an enzyme necessary for the coronavirus replication process. The U.S. has ordered 20 million courses of Paxlovid treatment, and the U.K. has ordered 2.75 million. SVB Leerink analyst Geoffrey Porges predicts that Paxlovid will generate more than $24 billion in revenue this year and $29.7 billion in vaccines, according to FiercePharma. That amounts to more than $50 billion in revenue from the coronavirus program alone. Of course, investors are most concerned about what will happen to these revenues in a post-pandemic world. Right now, it's impossible to accurately predict the level of revenue from the coronavirus program in the future. And that represents uncertainty. Nevertheless, experts say the coronavirus will exist. And that means we will need remedies and treatments. So we can probably expect a satisfactory level of revenue from coronavirus-related products for quite some time. But here's the best news: Pfizer is far from being a coronavirus-only company. The company's nine-month earnings report shows that at least six products are generating blockbuster revenue. And in the third quarter, the company says, revenue excluding the coronavirus vaccine rose 7 percent to more than $11 billion. As if that weren't enough, Pfizer has something else to like. And that's the pipeline. The company is working on 94 programs -- 29 of which are in Phase 3 and nine of which are in the registration phase. That means we may see a new batch of drugs in the not-too-distant future. This is important because the patent on some of Pfizer's drugs expires at the end of this decade. The blood-thinning drug Eliquis, for example, will lose protection in 2028. This is a standard part of life for a pharmaceutical company - and that's why it's important to have a strong product portfolio to make up for future patent expirations. Now let's look at the valuation. As mentioned earlier, Pfizer's stock price has risen slightly. But it is still trading at very reasonable levels. It trades at only 8.5 times projected earnings. In addition, Pfizer pays a solid dividend, with a yield of over 2.8%. So should you invest in Pfizer in 2022? Well, now seems like a good time to do so. The company generates billions of dollars in revenue from its coronavirus vaccine program. It has a portfolio of non-coronavirus drugs and a full cycle of late-stage research. The stock looks inexpensive -- and an investment in this major pharmaceutical player will provide you with passive income in the form of dividends. All of this is a great formula for success this year and in the years to come.
NYSE:PFELong
by FOREXN1
4